Brad Loncar weighs in on JNJ, MRNA, PFE, VRTX, IBB, XBI, SRNE, and VIR. He says that investors should be skeptical of biotech companies that suddenly announce clinical trial news as these stocks will eventually be valued on the fundamentals.
Market Overtime
29 Jan 2021
Market Overtime
27 Jan 2021
The Watch List
16 Nov 2020
The Watch List
30 Nov 2020
The Watch List
15 Jan 2021
MID-DAY Movers
29 Jan 2021
Brad Loncar weighs in on JNJ, MRNA, PFE, VRTX, IBB, XBI, SRNE, and VIR. He says that investors should be skeptical of biotech companies that suddenly announce clinical trial news as these stocks will eventually be valued on the fundamentals.
Market Overtime
29 Jan 2021